Integra Therapeutics is focused on developing next-generation gene writing tools aimed at addressing genetic and oncological diseases with significant unmet medical needs. Their innovative technology platform, known as FiCAT, combines the precision of CRISPR-Cas systems with the transfer efficiency of an engineered piggyBac transposase protein. This unique combination allows for the effective delivery of both small and large genetic payloads, thereby overcoming some of the primary limitations associated with traditional gene therapy approaches, such as gene size and stability.

The company emphasizes the importance of improving the scope, efficiency, and safety of advanced therapies through their gene writing tools. By leveraging the capabilities of FiCAT, Integra Therapeutics aims to enhance the precision and stability of gene editing, ultimately contributing to more effective treatments for complex diseases. Their commitment to innovation is further underscored by recent developments, including licensing agreements and funding from the European Commission, which support their ongoing research and development efforts in the field of gene therapy.

Spain

At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases.

Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery.

Integra Therapeutics

Company Details